Neuland Laboratories Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/d2pnphl104qb4jadq1uvh4n5.pdf

Key Takeaways


CMS Business: The Core Growth Thesis

Saharsh Davuluri: "I think the way I would look at it or rather explain it is our CMS business comprises of both a baseline business as well as a development business. Today, Neuland is a kind of in a phase where are we are moving from development projects and we are moving our development projects into commercial projects."

Prime & GDS: The Drag

Sucheth Davuluri: "Aditya, we think that your concern is very similar to our concern as well. ... we got in touch with all our customers, we pulled the data from the market, we analyzed the market share of all the companies out there ... we also got feedback from our customers whether they have any accumulated inventory or have they lost market share."

Margins: Gross Up, Operating Flat


Balance Sheet & Cash Flow


Pipeline & Business Development

Saharsh Davuluri: "If you look at it from a quarter to quarter basis, it does show inconsistency, but the way I would look at our CMS business is look at it from a fairly long perspective, look at it over a 15 quarter period and if you look at it over a 15-20 quarter period, you would actually see that there is progression..."

Guidance & Commitments

CommitmentSpecificsTimeline
Levetiracetam volume recoveryVolumes expected to recover based on historical patternsComing quarters
Unit III breakevenUnit III expected to break evenFY23
Raw material price softening20% to 25% softening vs beginning of yearFull year FY23
CMS molecules commercializedMore molecules to be commercializedNext 12 months
Capacity adequacyExisting facilities adequate, Unit III has headroomAt least next 2 years
Growth resumptionBreak away from stagnation period, get back on growth trackFY23
Operating leverage benefitIf growth returns, much better EBITDA and PBT margins expectedFY23 (conditional on growth)

Key Metrics

MetricQ1 FY23
Total income₹221.7 cr, vs ₹202.9 cr in Q1 FY22
EBITDA₹29 cr, with margins of 13.1%, flat YoY (13.6% in Q1 FY22), down 220 bps QoQ
Gross margin46.1%, vs 41.5% in Q4 FY22 and 42.4% in Q1 FY22
Profit after tax₹9.8 cr, vs ₹8.6 cr in Q1 FY22
EPS₹7.7
CMS revenue~₹69 cr, over 50% growth YoY
CMS new projects added3 new projects in early stages during the quarter
CMS share of overall revenueOver 30%
Net debt₹160 cr, reduced from ₹212 cr QoQ; over ₹45-50 cr debt repaid in the quarter
Unit III remaining block to be depreciated~₹225 cr as of June end
Unit III annual operating expenses~₹60 cr (last year)
CAPEX in Q1₹15 cr, of which Unit III was ~₹2 cr
Full-year FY23 CAPEX plan₹70-80 cr
Raw material price impact estimated for full year~₹45 cr, based on spot prices
Expected raw material price softening for full year20-25% compared to beginning of the year
Levetiracetam volume decline15% decline in volumes